<DOC>
	<DOC>NCT01371461</DOC>
	<brief_summary>Overall improvement, severities and changes of specific clinical symptoms were surveyed in outpatients with depression or in a depressed state to evaluate the efficacy and safety of PAXIL tablets in patients in whom the PAXIL dose was increased and those treated with a constant dose.</brief_summary>
	<brief_title>Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)</brief_title>
	<detailed_description />
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Subjects who is 18 years or more Subjects diagnosed with depression or in a depressed state Subjects who have been treated with paroxetine prior to this investigation Subjects with hypersensitivity to paroxetine Subjects taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs Concomitant use in subjects taking pimozide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>